Metastatic Ovarian Cancer Clinical Trial
Official title:
Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring
HE4 is a new marker that could improve the detection of ovarian cancer. The HE4 assay may have an advantage over the CA-125 assay in that it is less frequently positive in patients with non malignant disease. Since the evaluation of HE4 for detection and diagnosis of ovarian cancer is well known, the behaviour of the marker during chemotherapy and follow-up period after treatment in metastatic ovarian cancer should be studied. It could be used in patient with non CA-125 secretary tumors. Prognosis and predictive value of HE4 should be compared with information provided by CA-125. The kinetics of HE4 values after treatment should be also analysed to determine the role that HE4 could play in the detection of recurrences during the follow-up of metastatic patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03634150 -
Safety and Efficacy of IV Nerofeā¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03287674 -
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05796973 -
Measuring Oncological Value of Exercise and Statin
|
Phase 3 | |
Terminated |
NCT03277482 -
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
|
Phase 1 | |
Completed |
NCT02482090 -
TIL Therapy for Metastatic Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03150992 -
EDMONd - Elemental Diet in Bowel Obstruction
|
N/A | |
Recruiting |
NCT03412526 -
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
|
Phase 2 | |
Recruiting |
NCT01174121 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
|
Phase 2 | |
Recruiting |
NCT04611126 -
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03242993 -
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
|
Phase 1 |